Chimerix Inc. (NASDAQ:CMRX) shares hit a new high on Thursday with the biotechnology firm continuing to get a boost from its decision to increase a test program for a virus-fighting drug so it can try to save a cruelly ill 7-year-old boy. Chimerix Inc. (NASDAQ:CMRX) stock performance was 2.80% in last session and finished the day at $27.14. Traded volume was 477,612.00 shares in the last session and the average volume of the stock remained 283,197.00 shares. Chimerix Inc. (NASDAQ:CMRX) insider ownership is 6.90%.

Tesaro Inc. (NASDAQ:TSRO) announced Thursday morning that it has entered into an exclusive, worldwide license agreement and immuno-oncology antibody collaboration with AnaptysBio Inc. TESARO Inc. (NASDAQ:TSRO) dropped -5.40% to $36.76 yesterday on volume of 732,104.00 shares. The intra-day range of the stock was $36.02 – $39.12. TESARO Inc. (NASDAQ:TSRO) has a market capitalization of 1.19 billion.

Albany Molecular Research (NASDAQ:AMRI) was upgraded by analysts at TheStreet from a hold rating to a buy rating. The analysts wrote, “Albany Molecular Research (AMRI) has been upgraded by TheStreet Ratings from hold to buy. The company’s strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows low profit margins. Albany Molecular Research, Inc. (NASDAQ:AMRI)’s stock on March 14, 2014 reported a higher of 9.49% to the closing price of $18.81. Its fifty two weeks range is $8.92 – $18.95. The total market capitalization recorded 603.54 million. The overall volume in the last trading session was 851,805.00 shares. In its share capital, Albany Molecular Research, Inc. (NASDAQ:AMRI) has 32.09 million outstanding shares.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of central nervous system disorders. On Friday, shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) advanced 0.68% to close the day at $17.65. Company return on investment (ROI) is -46.30% and its monthly performance is recorded as 40.53%. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) quarterly revenue growth is 89.17%.